Curadel Pharma understands the interest in accessing its zwitterionic radiotherapies outside of clinical trials and prior to regulatory approval. However, our primary focus is to complete clinical trials and obtain regulatory approval to make this technology available as quickly as possible. As such, we do not currently offer expanded access programs. Participation in our clinical trials is the most appropriate way to access our drugs at this time. Information about our clinical trials, including eligibility criteria and locations, is available at https://www.clinicaltrials.gov.